NEUROCYCLE THERAPEUTICS
Neurocycle Therapeutics is a biopharmaceutical company that focuses on sub-type selective GABA-A modulation. By selectively targeting a newly-identified mechanism of action, their lead candidate (NCT10004) effectively reduced itch to near-baseline levels across a broad range of models including allergic and contact dermatitis models. Their selective compounds also produced significant relief of chronic pain in multiple studies and showed excellent efficacy in models of epilepsy. These compounds... act quickly, do not suppress the immune system, show no signs of dependency/addiction, and do not lose efficacy over time. Their objective is to deliver next-generation treatments for the itch, pain, and certain refractory forms of pediatric epilepsy that are superior or complementary to existing treatments.
NEUROCYCLE THERAPEUTICS
Social Links:
Industry:
Biotechnology
Founded:
2016-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.neurocycletherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
10 K CHF
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Google Twitter Timeline Google DNS Google Domains Google Cloud DNS
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Founder
Investors List
Venture Kick
Venture Kick investment in Grant - Neurocycle Therapeutics
Official Site Inspections
http://www.neurocycletherapeutics.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Neurocycle Therapeutics"
Neurocycle Therapeutics - Crunchbase Company Profile & Funding
Neurocycle Therapeutics is a biopharmaceutical company that focuses on sub-type selective GABA-A modulation. By selectively targeting a newly-identified mechanism of action, their …See details»
Precision Neuroscience, Transformational Therapies
Addressing the needs of patients with devastating and life-limiting disorders is central to our focus. Our scientific expertise in molecular mechanisms and the complex neurocircuitry underlying disorders of the nervous system is driving …See details»
Engrail Therapeutics Acquires NeuroCycle Therapeutics
Feb 2, 2021 · SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeuticsâ„¢ (Engrail) today announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type …See details»
NeuroCycle Therapeutics - PitchBook
Opeartor of a pharmaceutical company intended to treat serious inflammatory and neurological disorders. The company focuses on selectively targeting specific receptor subtypes to treat diseases related to central sensitization including …See details»
Engrail Therapeutics acquires Neurocycle Therapeutics - 2021-02 …
Feb 2, 2021 · Neurocycle Therapeutics Neurocycle Therapeutics is a biopharmaceutical company that focuses on sub-type selective GABA-A modulation.See details»
NeuroCycle Therapeutics - Products, Competitors, Financials, …
NeuroCycle Therapeutics is a biopharmaceutical company. It discovers and develops therapeutics that act within the central nervous system to treat serious inflammatory and neurological …See details»
Engrail Therapeutics Acquires NeuroCycle Therapeutics
Feb 2, 2021 · Founded in 2019, Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to...See details»
NeuroCycle Therapeutics - Craft
NeuroCycle Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule drugs that target the central nervous …See details»
NeuroCycle Therapeutics gets acquired by San Diego …
Aug 18, 2021 · Beginning 2021, Engrail Therapeuticsâ„¢ (Engrail) - forging a new direction to reduce the enormous burden of diseases that impact the nervous system - announced that it has acquired NeuroCycle Therapeutics, a …See details»
Neurocycle Therapeutics - Contacts, Employees, Board Members, …
Neurocycle Therapeutics is a biopharmaceutical company that focuses on sub-type selective GABA-A modulation.See details»
NeuroCycle Therapeutics | ETH Zurich - ETH Zürich
NeuroCycle Therapeutics was acquired by Engrail Therapeutics as part of their efforts to build a leading, patient-centric neuroscience company. Nebion's sub-type selective GABA-A …See details»
Wilson Sonsini Advises NeuroCycle Therapeutics on Acquisition by ...
On February 2, 2021, Engrail Therapeutics announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation. The acquisition …See details»
NeuroCycle Therapeutics Awarded NIH SBIR Grant to Study Next …
Feb 13, 2019 · NeuroCycle Therapeutics, Inc. is a privately held pharmaceutical company unlocking the potential of small-molecule CNS therapeutics to transform patient's lives.See details»
NeuroCycle Therapeutics Awarded NIH HEAL Initiative Grant to …
Oct 1, 2019 · NeuroCycle Therapeutics, Inc. is a privately held pharmaceutical company working to unlock the potential of subtype-selective CNS therapeutics to transform patient's lives.See details»
Engrail Therapeutics Announces Positive Results of ENX-101 Phase …
SAN DIEGO – June 7, 2022 – Engrail Therapeuticsâ„¢ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of …See details»
NeuroCycle Gets $500K NINDS Grant to Study Dravet Therapies
Feb 28, 2019 · The National Institute of Neurological Disorders and Stroke (NINDS) has awarded NeuroCycle Therapeutics a $500,000 grant to test advanced subtype-selective GBAA receptor …See details»
NeuroCycle Therapeutics Awarded NIH SBIR Grant to Study Next …
Feb 13, 2019 · This grant builds upon the company's strategy to develop a portfolio of small molecule drug candidates that maximize efficacy and minimize side effects through selective …See details»
NeuroCycle Therapeutics Awarded NIH HEAL Initiative Grant to
Oct 1, 2019 · Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.See details»
NCT-10004 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 · Understand key drug designations in just a few clicks with Synapse. NCT-10004: a GABAA receptor modulators Drug, Initially developed by NeuroCycle Therapeutics, Inc.,See details»
NCT-10015 - Drug Targets, Indications, Patents - Synapse - Patsnap
NCT-10015, Initially developed by NeuroCycle Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Nervous System Diseases,Other Diseases, Active …See details»